Should we use montelukast in wheezy children? by Haq I et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Haq I, Harris C, Taylor J, McKean MC, Brodlie M.  
Should we use montelukast in wheezy children? 
Archives of Disease in Childhood (2017) 
DOI: https://doi.org/10.1136/archdischild-2017-312655  
 
 
Copyright: 
This article has been accepted for publication in Archives of Disease in Childhood following peer review. 
The definitive copyedited, typeset version is available online at:  
https://doi.org/10.1136/archdischild-2017-312655  
 
Date deposited:   
09/08/2017 
 
Should we use montelukast in wheezy children? 
 
Iram Haq1,2#, Caroline Harris2#, Jake Taylor3#, Michael C McKean2 and Malcolm 
Brodlie1,2* 
 
1Institute of Cellular Medicine, Newcastle University 
2Paediatric Respiratory Medicine, Great North Children’s Hospital, Newcastle upon 
Tyne Hospitals NHS Foundation Trust 
3Medical School, Newcastle University 
 
#Equal contributions made 
 
*Corresponding author: Malcolm Brodlie, MRC Clinician Scientist/Clinical Senior 
Lecturer, Honorary Consultant in Paediatric Respiratory Medicine. Level 3, Clinical 
Resource Building, Great North Children’s Hospital, Queen Victoria Road, Newcastle 
upon Tyne, NE1 4LP. United Kingdom.  
Telephone: 0191 2825454  
E-mail: malcolm.brodlie@ncl.ac.uk 
 
Key words: asthma; montelukast; wheeze; children; leukotriene receptor antagonist 
 
Word count: 1246 (including suggested subheadings) 
  
The scale of the problem 
 
Children who wheeze represent a major public health issue and an ongoing clinical 
challenge in paediatrics. Around a third of all pre-school children experience at least 
one episode of wheeze and 10% of school-aged children in the United Kingdom are 
prescribed asthma medication. Pertinently, difficult to control or severe asthma in 
individual children is still associated with substantial morbidity and sometimes 
preventable mortality on an unacceptable number of occasions in well-developed 
healthcare systems. 
 
It is imperative that we manage children in the most effective way possible. In the 
broadest sense this starts with the accurate diagnosis of wheeze, something in itself 
demonstrated to be not as straightforward as perhaps we would like to imagine. 
Then optimal treatment and educational strategies are required to prevent or 
minimise the severity of future episodes. Accurate phenotyping is necessary to 
determine the best treatment strategy as the causes and pathogenic mechanisms of 
wheezing in children are multifactorial. So, where does montelukast fit in to this 
model of care that we aspire to deliver? 
 
 
Scientific rationale for the use of montelukast and possible adverse effects 
 
Most would agree that the science underpinning leukotriene receptor antagonists 
(LTRAs) is intuitively sound. LTRAs block cysteinyl leukotriene receptors that are 
expressed on the surface of a range of effector cells known to be pivotal in the 
pathophysiology of wheeze. Leukotrienes are pro-inflammatory lipid mediators, 
principally released by mast cells, that trigger bronchoconstriction, eosinophil 
chemotaxis and mucus secretion in the airway. LTRAs are free of many of the 
adverse effects associated with (oral) corticosteroids in children. A daily tablet that 
may be chewable is also attractive to many families.  It is important to note however 
that behaviour change is well-recognised, which may be significant, along with very 
rare reports of Churg-Strauss syndrome.  
 
 
Clinical use of montelukast and the concept of different phenotypes in children who 
wheeze 
 
The translation of science from bench to bedside has not been completely 
straightforward however. The initial theoretical promise of LTRAs in children who 
wheeze has not been fulfilled and in “real life” terms, although some individual 
children experience clear benefit, treatment response in the majority often appears 
modest at best. However paediatric asthma guidelines are unanimous in their 
inclusion of LTRAs. At risk of over simplification, guidelines draw a distinction 
between pre-school children and those over 5; in addition, most clinicians recognise 
the broad phenotypes of younger children who only wheeze in association with viral 
respiratory tract infections, so-called episodic viral wheeze (EVW), and children with 
atopy and multiple-trigger wheeze (MTW) who tend to be older.  
 
Current BTS/SIGN guidelines for pre-school children advise that LTRAs be used as 
first-line add on preventer therapy after low dose ICS or as alternative monotherapy 
where ICS are not tolerated.1 However, the distinction between EVW and MTW 
management is not entirely clear in recent practice recommendations. For children 
over 5, LTRA use is recommended as second-line add-on therapy where control is 
inadequate despite combined treatment with a long-acting beta-2 agonist (LABA) 
and higher-dose ICS - a point where specialist referral may be required.1  
 
In pre-school children with EVW, montelukast has been evaluated in randomised 
controlled trials (RCTs) both as maintenance (preventer) and episodic (symptomatic) 
treatment. Individual RCTs varied in methodology, but in summary some subtle 
clinical benefit has been demonstrated from episodic montelukast use with reduction 
in health resource utilisation by around a third (OR 0.65, 95% CI 0.47-0.89) 
compared to placebo,2 and of reduced severity in symptoms3 (respiratory distress 
and disruption of activity), again by about a third.2 3 As maintenance therapy the 
PREVIA study found a statistically significant reduction in exacerbation rates, by 
around a third (1.60 versus 2.34 episodes/year).4 In another large RCT maintenance 
montelukast was not associated with a reduced number of acute episodes however 
but there was a slight reduction in symptom scores.5  A Cochrane review did not find 
evidence to support maintenance or episodic montelukast in children with EVW for 
the primary review outcome of reduction in requirement for rescue oral 
corticosteroids.6 
 
Most recently the WAIT trial randomised 1358 pre-school children with two or more 
previous episodes to receive montelukast or placebo at the onset of wheeze.7 
Findings for the primary outcome of unscheduled medical attendances for wheeze 
were negative. However, in a pre-defined subgroup of children with a 5/5 
polymorphism in the ALOX5 promoter gene, which is involved in arachidonic acid 
metabolism, there was some benefit demonstrated (2·0 versus 2·4 unscheduled 
attendances/year; IRR 0·80, 95% CI 0·68–0·95; p=0·01).7  
 
Montelukast has also been studied in young children after respiratory syncytial virus 
bronchiolitis. A large RCT found no difference in respiratory symptoms, including 
wheeze, in the montelukast group versus placebo.8  
 
Although studies are limited in pre-school children with MTW, an RCT of 689 
children comparing montelukast to placebo showed statistically significant, but 
arguably clinically modest, improvements in symptom scores by day and night, 
requirement for bronchodilators and oral corticosteroids and symptom-free days.9 
Smaller studies have also shown reductions in bronchoconstrictive response to cold-
triggered symptoms and airway hyper-responsiveness following montelukast. It is 
important to note however that there is clear evidence for superior efficacy of ICS 
over LTRAs as monotherapy for children with MTW confirming their respective 
positions in guidelines.10  
 
In terms of LTRAs as add-on therapy in children evidence is limited, partly due to a 
shortage of good quality studies. A Cochrane review including 4 studies involving 
children aged 6-18 years found no significant difference in exacerbation rates 
between ICS and LTRA combination treatment and ICS alone at the same or 
increased dose.11 The BADGER trial randomised children aged 6-17 years with 
poorly controlled asthma on fluticasone 200mcg/day to receive add-on treatment in 
varying sequence in the form of a LABA (salmeterol), montelukast or increased 
fluticasone dose.12 A beneficial response to salmeterol was most likely compared to 
montelukast (relative probability 1.6, 95% CI 1.1-2.3, p=0.004) or increased ICS 
dose (relative probability 1.7, 95% CI 1.2-2.4, p=0.005).12 Importantly, there was 
variation in response and some individual children responded best to LTRA or 
increased ICS dose. 
 
 
In pursuit of precision medicine, a pragmatic way forward 
 
One explanation for the varied results of studies discussed above is the increasingly 
recognised complex and dynamic heterogeneity of different endotypes in children 
who wheeze. This concept resonates with experiences of healthcare professionals 
who frequently manage children who wheeze and observe varying treatment 
responses and individual trajectories over time and with those who wrestle with the 
careful design of studies to objectively measure the efficacy of therapeutic 
interventions or who study the complex inter-related pathways and mechanisms 
involved in the pathophysiology of airway disease.  
 
A major challenge is to successfully identify practical biomarkers or other tools to 
accurately, cost-effectively and rapidly select the right treatment for an individual 
child at the right time. Arguably the ALOX5 polymorphism subgroup in the WAIT 
study may provide a glimpse of this but genome sequencing is not yet a practical 
option at the clinical coal-face. In the absence of these key tools for precision 
medicine the most appropriate way forward for the thoughtful clinician is to perform 
an ‘n of 1’ therapeutic trial in an individual patient to assess potential benefit from 
montelukast. Such a trial should be as objective as possible and finite in length 
remembering the variable natural history of children who wheeze. Undoubtedly a 
significant minority of children will benefit from montelukast and this approach would 
appear the most effective way to identify such children, while minimising needless 
over-prescription to children who do not benefit. 
  
Funders: MB funded by Medical Research Council Clinician Scientist fellowship 
(MR/M008797/1). 
 
Competing interests: MB reports outside the submitted work investigator-led grants 
from Pfizer and Roche Diagnostics and personal fees paid to Newcastle University 
from Novartis. No other authors have any competing interests. 
 
Contributorship statement: IH, CH and JT: Performed literature reviews and wrote 
draft sections, all contributed to and approved the final version. MCM: Commented 
and approved the final version. MB: Drafted the initial version and completed the 
final version.            
 
 
  
References 
 
1. BTS/SIGN. British guideline on the management of asthma: BTS/SIGN, 2016. 
2. Robertson CF, Price D, Henry R, et al. Short-course montelukast for intermittent 
asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 
2007;175(4):323-9. doi: 10.1164/rccm.200510-1546OC 
3. Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled 
corticosteroid or leukotriene receptor antagonist in preschool children with 
moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 
2008;122(6):1127-35 e8. doi: 10.1016/j.jaci.2008.09.029 
4. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma 
exacerbations in 2- to 5-year-old children with intermittent asthma. Am J 
Respir Crit Care Med 2005;171(4):315-22. doi: 10.1164/rccm.200407-894OC 
5. Valovirta E, Boza ML, Robertson CF, et al. Intermittent or daily montelukast 
versus placebo for episodic asthma in children. Ann Allergy Asthma Immunol 
2011;106(6):518-26. doi: 10.1016/j.anai.2011.01.017 
6. Brodlie M, Gupta A, Rodriguez-Martinez CE, et al. Leukotriene receptor 
antagonists as maintenance and intermittent therapy for episodic viral wheeze 
in children. Cochrane Database Syst Rev 2015(10):CD008202. doi: 
10.1002/14651858.CD008202.pub2 
7. Nwokoro C, Pandya H, Turner S, et al. Intermittent montelukast in children aged 
10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, 
placebo-controlled trial. Lancet Respir Med 2014;2(10):796-803. doi: 
10.1016/S2213-2600(14)70186-9 
8. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment 
of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in 
children. Am J Respir Crit Care Med 2008;178(8):854-60. doi: 
10.1164/rccm.200706-910OC 
9. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor 
antagonist, for the treatment of persistent asthma in children aged 2 to 5 
years. Pediatrics 2001;108(3):E48. 
10. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled 
corticosteroids in the management of recurrent and/or chronic asthma in 
adults and children. Cochrane Database Syst Rev 2012(5):CD002314. doi: 
10.1002/14651858.CD002314.pub3 
11. Chauhan BF, Ben Salah R, Ducharme FM. Addition of anti-leukotriene agents to 
inhaled corticosteroids in children with persistent asthma. Cochrane Database 
Syst Rev 2013(10):CD009585. doi: 10.1002/14651858.CD009585.pub2 
12. Lemanske RF, Jr., Mauger DT, Sorkness CA, et al. Step-up therapy for children 
with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 
2010;362(11):975-85. doi: 10.1056/NEJMoa1001278 
 
